Cancer Search logoCancer Search
  1. Home
  2. Cancer Clinical Trials
  3. 91 Deficient DNA Mismatch Repair (dMMR) Cancer Clinical Trials

Deficient DNA Mismatch Repair (dMMR)
{name}
{subtitle}
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
826 sites for NCT02465060
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type
Recruiting
Phase 2
link NCT02465060
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
city
657 sites for NCT02912559
biomarker
Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers
condition
Colon Adenocarcinoma, +1 more condition
drug
atezolizumab, +3 more drugs
drug type
chemotherapy, +1 more type
Recruiting
Phase 3
link NCT02912559
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
city
146 sites for NCT04008030
biomarker
Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers
condition
Colorectal Carcinoma
drug
ipilimumab, +1 more drug
drug type
immunotherapy
Recruiting
Phase 3
link NCT04008030
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
city
332 sites for NCT02997228
biomarker
Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers
condition
Colorectal Adenocarcinoma
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +2 more types
Recruiting
Phase 3
link NCT02997228
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
city
191 sites for NCT04214067
biomarker
Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers
condition
Endometrial Endometrioid Adenocarcinoma
drug
brachytherapy, +2 more drugs
drug type
immunotherapy, +1 more type
Recruiting
Phase 3
link NCT04214067
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Advanced Rectal Cancer
city
116 sites for NCT04751370
biomarker
Deficient DNA Mismatch Repair (dMMR), +1 more biomarker
condition
Rectal Adenocarcinoma
drug
ipilimumab, +3 more drugs
drug type
immunotherapy, +2 more types
Recruiting
Phase 2
link NCT04751370
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
city
259 sites for NCT03609216
biomarker
ARID1A Loss, +122 more biomarkers
condition
Bladder Urothelial Carcinoma
drug
chemoradiotherapy, +6 more drugs
drug type
chemotherapy, +3 more types
Recruiting
Phase 2
link NCT03609216
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
city
25 sites for NCT02628067
biomarker
Deficient DNA Mismatch Repair (dMMR), +6 more biomarkers
condition
Anal Squamous Cell Carcinoma, +18 more conditions
drug
pembrolizumab
drug type
immunotherapy
Recruiting
Phase 2
link NCT02628067
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
city
83 sites for NCT02715284
biomarker
Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers
condition
Endometrial Carcinoma, +11 more conditions
drug
dostarlimab
drug type
immunotherapy
Recruiting
Phase 1
link NCT02715284
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
city
48 sites for NCT04632992
biomarker
AKT1 Mutation, +17 more biomarkers
condition
Malignant Solid Tumor
drug
ado-trastuzumab emtansine, +11 more drugs
drug type
chemotherapy, +2 more types
Recruiting
Phase 2
link NCT04632992
Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
city
31 sites for NCT04895722
biomarker
Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers
condition
Colorectal Adenocarcinoma
drug
MK-1308A, +4 more drugs
drug type
immunotherapy
Recruiting
Phase 2
link NCT04895722
Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
city
1 site for NCT04157985
biomarker
Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers
condition
Adenocarcinoma of the Gastroesophageal Junction, +16 more conditions
drug
anti-PD-1 antibody, +1 more drug
drug type
immunotherapy
Recruiting
Phase 3
link NCT04157985
91 Items
Page 1 of 8
Open Page 2  →
Main Menu
Clinical Trials
Therapies
Biomarkers
Cancer Types
Drugs
About
Cancer Search
Terms
Site Map
Credits
FAQ
Powered By
GenomOncology, LLC Logo
Copyright © 2022 GenomOncology, LLC